Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605416 | 0.88 | FKBP1A (0.49) | KLK5ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL7359670 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1TSHRCYP1A2 | |
| SCHEMBL11349826 | 0.81 | ELANE (0.52) | ELANEALDH1A1MAPT | |
| SCHEMBL30119875 | 0.80 | CYP1A2 (0.46) | MGLLALDH1A1KMT2AMEN1DPP4 | |
| SCHEMBL29703825 | 0.79 | F2 (0.40) | ALDH1A1KMT2ADPP4DPP8DPP7 | |
| SCHEMBL10706625 | 0.79 | CYP1A2 (0.48) | ALDH1A1KMT2AMEN1CYP1A2CYP2D6 | |
| SCHEMBL6468703 | 0.79 | KLK5 (0.53) | MMP1MMP13MMP9KLK5ALDH1A1 | |
| SCHEMBL14235217 | 0.79 | KLK5 (0.53) | MMP1MMP13MMP9KLK5ALDH1A1 | |
| SCHEMBL6160675 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1TSHRCYP1A2 | |
| SCHEMBL7068808 | 0.78 | BCL9 (0.56) | MGLLALDH1A1KMT2ACYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050208480-A1 | aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | VICTORIA EDWARD J | 2005-09-22 | — | — | US | disclosed |
| US-20040009904-A1 | APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | VICTORIA EDWARD JESS (US) | 2004-01-15 | — | — | US | disclosed |
| US-6410775-B1 | HYDROPHILIC COUPLING | LA JOLLA PHARMACEUTICAL COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-6207160-B1 | POLYPEPTIDES | LA JOLLA PHARMACEUTICAL COMPANY | 2001-03-27 | — | — | US | disclosed |
| EP-0954531-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | Lajolla Pharmaceutical Company (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0833648-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | JOLLA PHARMA (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0954531-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1999-08-31 | — | — | EP | disclosed |
| WO-1997046251-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1998-06-04 | — | — | WO | disclosed |
| EP-0833648-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997046251-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1996040197-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009904-A1 | APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | CD4, VSIG8, PTMS | MMP1 4065/4885MMP13 3901/4885MMP9 4452/4885 |
| US-20050208480-A1 | aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | CD4, VSIG8, PTMS | MMP1 4065/4885MMP13 3901/4885MMP9 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.